ArticleMolecules (Basel, Switzerland)2019

Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy.

Adam Bohr et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.